Clinical Trial

Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients

Study acronym: ImmBridge
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-02.
Status change: Not Yet Recruiting → Recruiting 2025-09-05
Trial Details
NCT Number NCT06918834
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Myelodysplastic Syndromes
Enrollment 236 participants
Start Date 2025-07-24
Primary Completion 2028-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-12